Covid-19 Monoclonal Antibody Therapy Infusion
The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for monoclonal antibody treatments bamlanivimab and Regeneron’s casirivimab/imdevimab for the treatment of mild to moderate COVID-19 in patients with positive results of direct SARS-CoV-2 viral testing. Bamlanivimab and casirivimab/imdevimab are interchangeable.
If you have recently been diagnosed with COVID-19, there may be treatment options available to you.
Please note that for this treatment to be impactful, it must be given within 10 days of developing COVID-19 symptoms.
Holistic Home & Hospice is offering a treatment known as monoclonal antibody infusion to help patients who have been diagnosed with COVID-19 and are at risk of developing a severe case of the illness. Early clinical trials have shown that this treatment may reduce the need for hospitalization and severe illness.
Information & eligibility
What is monoclonal antibody treatment for COVID-19?
Antibodies are naturally made in our bodies to fight infection. When our immune system meets a new foreign substance in the body, it makes new antibodies that attack the foreign substance. The next time that substance shows up, our immune system can produce the same antibodies to help the body fight it off before it can make a person sick. These types of naturally occurring antibodies provide active immunity. Monoclonal antibodies are laboratory-made proteins designed to mimic the body’s ability to fight off viruses and pathogens.
Monoclonal antibody treatment for COVID-19 has received emergency use authorization by the Food and Drug Administration (FDA) as an investigational medicine used for the treatment of COVID-19 patients at high-risk of developing severe illness.
Who may be eligible to receive monoclonal antibody treatment?
Patients who have a positive COVID-19 test but are not hospitalized and are:
- 12 years or older
- Weigh more than 88 pounds
- Experiencing mild to moderate symptoms such as cough, fatigue, loss of appetite, and fever for less than 10 days
- At risk to get very sick from COVID-19
High-risk factors for serious illness from COVID-19 include:
- Age 65 or older
- Obesity (body mass index (BMI) greater than 35)
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease
- Currently receiving immunosuppressive treatment
- 55 or older with cardiovascular disease, uncontrolled hypertension or chronic pulmonary (lung) disease
Pediatrics: Treatment eligibility
Children between 12 and 17 years old who have certain conditions may meet the criteria. Consult with a pediatrician to discuss eligibility.
Patients who are 12-17 years old and who have any of the following indicators may also benefit
- BMI ≥85th percentile for their age and gender based on CDC growth charts, OR
- Sickle cell disease, OR
- Congenital or acquired heart disease, OR
- Neurodevelopmental disorders, for example, cerebral palsy, OR
- A medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
- Asthma, reactive airway or other chronic respiratory disease that requires daily medication for control
These therapies are not authorized for use in patients who:
- Are hospitalized due to COVID-19
- Require oxygen therapy due to COVID-19
- Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to an underlying non-COVID-19-related comorbidity
- Are pregnant or breastfeeding
- Have an active serious fungal or bacterial infection
- Have planned surgery within the next 7 days or any underlying severe medical condition other than COVID-19 that is deemed life threatening within next 29 days
Requesting an infusion
Please note that a physician referral is required to be eligible for this treatment. Talk with your physician to determine if you meet medical requirements.
